We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · November 14, 2020

Ticagrelor vs Clopidogrel in Terms of Net Adverse Clinical Events in Patients With ACS Undergoing PCI

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
JAMA 2020 Oct 27;324(16)1640-1650, SC You, Y Rho, B Bikdeli, J Kim, A Siapos, J Weaver, A Londhe, J Cho, J Park, M Schuemie, MA Suchard, D Madigan, G Hripcsak, A Gupta, CG Reich, PB Ryan, RW Park, HM Krumholz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading